Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence

Journal of Addictive Diseases

Volumn 25, Issue 4, 2006, Pages 91-103

  Kissin, Wendy ^a   McLeod, Caroline ^a   Sonnefeld, Joseph ^a   Stanton, Arlene ^b  

^a WESTAT   (United States)

^b SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

Buprenorphine; DATA 2000; Medication assisted treatment; Opioid dependence

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; NALTREXONE; OXYCODONE;

ARTICLE; DATA ANALYSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN; PRESCRIPTION; WITHDRAWAL SYNDROME;

ATTITUDE OF HEALTH PERSONNEL; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DOCUMENTATION; HEALTH PERSONNEL; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTIONS, DRUG; PROFESSIONAL COMPETENCE; QUESTIONNAIRES;

EID: 33750696944     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n04_09     Document Type: Article

References (34)

1. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280:1936-1943.
2. Drug Addiction Treatment Act of 2000, 42 USC§3502a, (2000).
3. NIDA. Buprenorphine Update: Questions and Answers. NIDA 2001; Available at: URL: http:// 165.112.78.61/Bupupdate.html. Accessed April 4, 2005.
4. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Center for Substance Abuse Treatment, US Dept of Health and Human Services; 2004. DHHS Publication No (SMA) 04-3939. Treatment Improvement Protocol (TIP) Series 40.
5. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988 January;43(1):72-8.
6. Chadderton A. Clinical issues in using buprenorphine in the treatment of opiate dependence. Drug and Alcohol Review 2000;19:329-35.
7. Woods JH, France CP, Winger GD. Behavioral pharmacology of buprenorphine: Issues relevant to its potential in treating drug abuse. NIDA Res Monogr 1992;121:12-27.
8. Vignau J, Duhamel A, Catteau J et al. Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat 2001 October; 21:135-44.
9. Thirion X, Micallef J, BarrauKet al. Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend 2001;61:281-5.
10. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs. buprenorphine in France. JAMA 2001;285:45.
11. Lepere B, Gourarier L, Sanchez M et al. Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments [in French]. Ann Med Interne (Paris) 2001;152(Suppl 3):IS5-12.
12. De Ducla M, Gagnon A, Mucchielli A, Robinet S, Vellay A. Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians [in French]. Ann Med Interne (Paris) 2000; 151(suppl A):A27-A32.
13. Buprenorphine replacement therapy: A confirmed benefit. Prescrire Int 1999;8(42):124-7.
14. Fhima A, Henrion R, Lowenstein W, Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex) [in French]. Ann Med Interne (Paris) 2001;152 (suppl 3):IS26-IS36.
15. O'Connor PG, Oliveto AH, Shi JM et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 1996; 22:523-31.
16. Resnick RB, Galanter M, Resnick E, Pycha C. Buprenorphine treatment of heroin dependence (detoxification and maintenance) in a private practice setting. J Addict Dis 2001;20:75-83.
17. Amass L, Ling W, Freese TE et al. Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. Am J Addict 2004;13(supple 1):S42-S66.
18. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-5.
19. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995;40:17-25.
20. Johnson RE, Strain EC, Amass L. Buprenorphine: How to use it right. Drug Alcohol Depend 2003; 70(suppl 2):S59-S77.
21. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002;36:312-21.
22. Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson CE. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002;160:344-52.
23. Ling W, Charuvastra C, Collins JF et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998; 93:475-86.
24. Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999;56:191-203.
25. Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco JL. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001;96:1433-41.
26. Overview of Findings from the 2002 National Survey on Drug Use and Health. Rockville, MD: Office of Applied Studies, US Dept of Health and Human Services; 2003. DHHS Publication Number SMA 03-3774; NHSDA Series H-21.
27. National Admissions to Substance Abuse Treatment Services. Treatment Episode Data Set (TEDS): 1992-2002. Rockville, MD: Office of Applied Studies, US Dept of Health and Human Services; 2004. DHHS Publication No. (SMA) 04-3965; DASIS Series S-23.
28. Mitka M. Office-based primary care physicians called on to treat the "new" addict. JAMA 2003;290(6): 735-6.
29. Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S. Barriers to the use of medications to treat alcoholism. Am J Addict 2003;12(4):281-94.
30. Thomas C. No magic bullet: Adoption of naltrexone by clinical providers [dissertation]. Waltham, Massachusetts: Florence Heller Graduate School, Brandeis University; 2000.
31. Stein B, Orlando M, Sturm R. The effect of copayments on drug and alcohol treatment following inpatient detoxification under managed care. Psychiatr Serv 2000;51:195-8.
32. West JC, Kosten TR, Wilk J et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict 2004;13 (suppl 1):S8-16.
33. Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction 1998;93:1567-75.
34. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-23.